Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients

Summary

A clinical study to assess the safety and efficacy of alternative regimens of primaquine for radical cure of vivax malaria in glucose 6-phosphate dehydrogenase (G6PD) deficient. G6PD deficient patients with P. vivax monoinfection will be treated with either weekly or delayed one-week course of primaquine, and the currently recommended by national guideline, 12-week chloroquine regimen to compare treatment safety among groups. All groups will be actively monitored for hemolysis during treatment and will have six-month follow-up period to assess treatment efficacy.

Timeline

Start

2018-07-20

Primary completion

2022-12-20

Completion

2023-07-06

Publications

• Barbosa L, Brito-Sousa J, Nascimento C, Pacheco A, Alexandre M, Alencar A, Melo M, Omena A, Souza I, Silva E, Queiroz M, Siqueira V, Rabelo C, Baia-da-Silva D, Silva D, Rocha Y, Barbosa A, Castro R, Almeida A, Brito M, Lopes A, Balieiro A, Costa M, Amaral T, Valle C, Vieira A, Gonzaga J, Pereira D, Alecrim M, Monteiro W, Lacerda M, Melo G. Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase-Deficient Patients in the Brazilian Amazon (ALTPRIM). Clin Infect Dis. 2025 Dec 24;81(5):e294-e301. doi: 10.1093/cid/ciaf007.

Drugs

Indications